Literature DB >> 27363491

Standardized evaluation of tumor-infiltrating lymphocytes in breast cancer: results of the ring studies of the international immuno-oncology biomarker working group.

Carsten Denkert1,2, Stephan Wienert1,3, Audrey Poterie4, Sibylle Loibl5,6, Jan Budczies1,2, Sunil Badve7, Zsuzsanna Bago-Horvath8, Anita Bane9, Shahinaz Bedri10, Jane Brock11, Ewa Chmielik12, Matthias Christgen13, Cecile Colpaert14, Sandra Demaria15, Gert Van den Eynden16, Giuseppe Floris17, Stephen B Fox18, Dongxia Gao19, Barbara Ingold Heppner1, S Rim Kim20, Zuzana Kos21, Hans H Kreipe13, Sunil R Lakhani22, Frederique Penault-Llorca23, Giancarlo Pruneri24, Nina Radosevic-Robin23, David L Rimm25, Stuart J Schnitt26, Bruno V Sinn1,27, Peter Sinn28, Nicolas Sirtaine29, Sandra A O'Toole30, Giuseppe Viale31, Koen Van de Vijver32, Roland de Wind33, Gunter von Minckwitz5, Frederick Klauschen1, Michael Untch34, Peter A Fasching35, Toralf Reimer36, Karen Willard-Gallo37, Stefan Michiels38, Sherene Loi39, Roberto Salgado16,40.   

Abstract

Multiple independent studies have shown that tumor-infiltrating lymphocytes (TIL) are prognostic in breast cancer with potential relevance for response to immune-checkpoint inhibitor therapy. Although many groups are currently evaluating TIL, there is no standardized system for diagnostic applications. This study reports the results of two ring studies investigating TIL conducted by the International Working Group on Immuno-oncology Biomarkers. The study aim was to determine the intraclass correlation coefficient (ICC) for evaluation of TIL by different pathologists. A total of 120 slides were evaluated by a large group of pathologists with a web-based system in ring study 1 and a more advanced software-system in ring study 2 that included an integrated feedback with standardized reference images. The predefined aim for successful ring studies 1 and 2 was an ICC above 0.7 (lower limit of 95% confidence interval (CI)). In ring study 1 the prespecified endpoint was not reached (ICC: 0.70; 95% CI: 0.62-0.78). On the basis of an analysis of sources of variation, we developed a more advanced digital image evaluation system for ring study 2, which improved the ICC to 0.89 (95% CI: 0.85-0.92). The Fleiss' kappa value for <60 vs ≥60% TIL improved from 0.45 (ring study 1) to 0.63 in RS2 and the mean concordance improved from 88 to 92%. This large international standardization project shows that reproducible evaluation of TIL is feasible in breast cancer. This opens the way for standardized reporting of tumor immunological parameters in clinical studies and diagnostic practice. The software-guided image evaluation approach used in ring study 2 may be of value as a tool for evaluation of TIL in clinical trials and diagnostic practice. The experience gained from this approach might be applicable to the standardization of other diagnostic parameters in histopathology.

Entities:  

Mesh:

Year:  2016        PMID: 27363491     DOI: 10.1038/modpathol.2016.109

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  20 in total

1.  An international study to increase concordance in Ki67 scoring.

Authors:  Mei-Yin C Polley; Samuel C Y Leung; Dongxia Gao; Mauro G Mastropasqua; Lila A Zabaglo; John M S Bartlett; Lisa M McShane; Rebecca A Enos; Sunil S Badve; Anita L Bane; Signe Borgquist; Susan Fineberg; Ming-Gang Lin; Allen M Gown; Dorthe Grabau; Carolina Gutierrez; Judith C Hugh; Takuya Moriya; Yasuyo Ohi; C Kent Osborne; Frédérique M Penault-Llorca; Tammy Piper; Peggy L Porter; Takashi Sakatani; Roberto Salgado; Jane Starczynski; Anne-Vibeke Lænkholm; Giuseppe Viale; Mitch Dowsett; Daniel F Hayes; Torsten O Nielsen
Journal:  Mod Pathol       Date:  2015-02-20       Impact factor: 7.842

2.  Triple-negative breast cancer: immune modulation as the new treatment paradigm.

Authors:  Mary L Disis; Sasha E Stanton
Journal:  Am Soc Clin Oncol Educ Book       Date:  2015

3.  The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014.

Authors:  R Salgado; C Denkert; S Demaria; N Sirtaine; F Klauschen; G Pruneri; S Wienert; G Van den Eynden; F L Baehner; F Penault-Llorca; E A Perez; E A Thompson; W F Symmans; A L Richardson; J Brock; C Criscitiello; H Bailey; M Ignatiadis; G Floris; J Sparano; Z Kos; T Nielsen; D L Rimm; K H Allison; J S Reis-Filho; S Loibl; C Sotiriou; G Viale; S Badve; S Adams; K Willard-Gallo; S Loi
Journal:  Ann Oncol       Date:  2014-09-11       Impact factor: 32.976

Review 4.  The immune system and response to HER2-targeted treatment in breast cancer.

Authors:  Giampaolo Bianchini; Luca Gianni
Journal:  Lancet Oncol       Date:  2014-02       Impact factor: 41.316

5.  Gene modules and response to neoadjuvant chemotherapy in breast cancer subtypes: a pooled analysis.

Authors:  Michail Ignatiadis; Sandeep K Singhal; Christine Desmedt; Benjamin Haibe-Kains; Carmen Criscitiello; Fabrice Andre; Sherene Loi; Martine Piccart; Stefan Michiels; Christos Sotiriou
Journal:  J Clin Oncol       Date:  2012-04-16       Impact factor: 44.544

6.  Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial.

Authors:  Gunter von Minckwitz; Andreas Schneeweiss; Sibylle Loibl; Christoph Salat; Carsten Denkert; Mahdi Rezai; Jens U Blohmer; Christian Jackisch; Stefan Paepke; Bernd Gerber; Dirk M Zahm; Sherko Kümmel; Holger Eidtmann; Peter Klare; Jens Huober; Serban Costa; Hans Tesch; Claus Hanusch; Jörn Hilfrich; Fariba Khandan; Peter A Fasching; Bruno V Sinn; Knut Engels; Keyur Mehta; Valentina Nekljudova; Michael Untch
Journal:  Lancet Oncol       Date:  2014-04-30       Impact factor: 41.316

7.  An international Ki67 reproducibility study.

Authors:  Mei-Yin C Polley; Samuel C Y Leung; Lisa M McShane; Dongxia Gao; Judith C Hugh; Mauro G Mastropasqua; Giuseppe Viale; Lila A Zabaglo; Frédérique Penault-Llorca; John M S Bartlett; Allen M Gown; W Fraser Symmans; Tammy Piper; Erika Mehl; Rebecca A Enos; Daniel F Hayes; Mitch Dowsett; Torsten O Nielsen
Journal:  J Natl Cancer Inst       Date:  2013-11-07       Impact factor: 13.506

8.  Tumor-infiltrating lymphocytes predict response to anthracycline-based chemotherapy in estrogen receptor-negative breast cancer.

Authors:  Nathan R West; Katy Milne; Pauline T Truong; Nicol Macpherson; Brad H Nelson; Peter H Watson
Journal:  Breast Cancer Res       Date:  2011-12-08       Impact factor: 6.466

9.  Prospective validation of immunological infiltrate for prediction of response to neoadjuvant chemotherapy in HER2-negative breast cancer--a substudy of the neoadjuvant GeparQuinto trial.

Authors:  Yasmin Issa-Nummer; Silvia Darb-Esfahani; Sibylle Loibl; Georg Kunz; Valentina Nekljudova; Iris Schrader; Bruno Valentin Sinn; Hans-Ullrich Ulmer; Ralf Kronenwett; Marianne Just; Thorsten Kühn; Kurt Diebold; Michael Untch; Frank Holms; Jens-Uwe Blohmer; Jörg-Olaf Habeck; Manfred Dietel; Friedrich Overkamp; Petra Krabisch; Gunter von Minckwitz; Carsten Denkert
Journal:  PLoS One       Date:  2013-12-02       Impact factor: 3.240

10.  Immunohistochemistry and fluorescence in situ hybridization assessment of HER2 in clinical trials of adjuvant therapy for breast cancer (NCCTG N9831, BCIRG 006, and BCIRG 005).

Authors:  Edith A Perez; Michael F Press; Amylou C Dueck; Robert B Jenkins; Chungyeul Kim; Beiyun Chen; Ivonne Villalobos; Soonmyung Paik; Marc Buyse; Anne E Wiktor; Reid Meyer; Melanie Finnigan; Joanne Zujewski; Mona Shing; Howard M Stern; Wilma L Lingle; Monica M Reinholz; Dennis J Slamon
Journal:  Breast Cancer Res Treat       Date:  2013-02-19       Impact factor: 4.872

View more
  80 in total

Review 1.  Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointestinal Tract Carcinomas, Non-Small Cell Lung Carcinoma and Mesothelioma, Endometrial and Ovarian Carcinomas, Squamous Cell Carcinoma of the Head and Neck, Genitourinary Carcinomas, and Primary Brain Tumors.

Authors:  Shona Hendry; Roberto Salgado; Thomas Gevaert; Prudence A Russell; Tom John; Bibhusal Thapa; Michael Christie; Koen van de Vijver; M V Estrada; Paula I Gonzalez-Ericsson; Melinda Sanders; Benjamin Solomon; Cinzia Solinas; Gert G G M Van den Eynden; Yves Allory; Matthias Preusser; Johannes Hainfellner; Giancarlo Pruneri; Andrea Vingiani; Sandra Demaria; Fraser Symmans; Paolo Nuciforo; Laura Comerma; E A Thompson; Sunil Lakhani; Seong-Rim Kim; Stuart Schnitt; Cecile Colpaert; Christos Sotiriou; Stefan J Scherer; Michail Ignatiadis; Sunil Badve; Robert H Pierce; Giuseppe Viale; Nicolas Sirtaine; Frederique Penault-Llorca; Tomohagu Sugie; Susan Fineberg; Soonmyung Paik; Ashok Srinivasan; Andrea Richardson; Yihong Wang; Ewa Chmielik; Jane Brock; Douglas B Johnson; Justin Balko; Stephan Wienert; Veerle Bossuyt; Stefan Michiels; Nils Ternes; Nicole Burchardi; Stephen J Luen; Peter Savas; Frederick Klauschen; Peter H Watson; Brad H Nelson; Carmen Criscitiello; Sandra O'Toole; Denis Larsimont; Roland de Wind; Giuseppe Curigliano; Fabrice André; Magali Lacroix-Triki; Mark van de Vijver; Federico Rojo; Giuseppe Floris; Shahinaz Bedri; Joseph Sparano; David Rimm; Torsten Nielsen; Zuzana Kos; Stephen Hewitt; Baljit Singh; Gelareh Farshid; Sibylle Loibl; Kimberly H Allison; Nadine Tung; Sylvia Adams; Karen Willard-Gallo; Hugo M Horlings; Leena Gandhi; Andre Moreira; Fred Hirsch; Maria V Dieci; Maria Urbanowicz; Iva Brcic; Konstanty Korski; Fabien Gaire; Hartmut Koeppen; Amy Lo; Jennifer Giltnane; Marlon C Rebelatto; Keith E Steele; Jiping Zha; Kenneth Emancipator; Jonathan W Juco; Carsten Denkert; Jorge Reis-Filho; Sherene Loi; Stephen B Fox
Journal:  Adv Anat Pathol       Date:  2017-11       Impact factor: 3.875

Review 2.  The Multifaceted Nature of Tumor Microenvironment in Breast Carcinomas.

Authors:  Laura Annaratone; Eliano Cascardi; Elena Vissio; Ivana Sarotto; Ewa Chmielik; Anna Sapino; Enrico Berrino; Caterina Marchiò
Journal:  Pathobiology       Date:  2020-04-23       Impact factor: 4.342

3.  PD-L1 expression and the immune microenvironment in primary invasive lobular carcinomas of the breast.

Authors:  Elizabeth D Thompson; Janis M Taube; Rebecca J Asch-Kendrick; Aleksandra Ogurtsova; Haiying Xu; Rajni Sharma; Alan Meeker; Pedram Argani; Leisha A Emens; Ashley Cimino-Mathews
Journal:  Mod Pathol       Date:  2017-07-21       Impact factor: 7.842

4.  Pitfalls in assessing stromal tumor infiltrating lymphocytes (sTILs) in breast cancer.

Authors:  Zuzana Kos; Elvire Roblin; Rim S Kim; Stefan Michiels; Brandon D Gallas; Weijie Chen; Koen K van de Vijver; Shom Goel; Sylvia Adams; Sandra Demaria; Giuseppe Viale; Torsten O Nielsen; Sunil S Badve; W Fraser Symmans; Christos Sotiriou; David L Rimm; Stephen Hewitt; Carsten Denkert; Sibylle Loibl; Stephen J Luen; John M S Bartlett; Peter Savas; Giancarlo Pruneri; Deborah A Dillon; Maggie Chon U Cheang; Andrew Tutt; Jacqueline A Hall; Marleen Kok; Hugo M Horlings; Anant Madabhushi; Jeroen van der Laak; Francesco Ciompi; Anne-Vibeke Laenkholm; Enrique Bellolio; Tina Gruosso; Stephen B Fox; Juan Carlos Araya; Giuseppe Floris; Jan Hudeček; Leonie Voorwerk; Andrew H Beck; Jen Kerner; Denis Larsimont; Sabine Declercq; Gert Van den Eynden; Lajos Pusztai; Anna Ehinger; Wentao Yang; Khalid AbdulJabbar; Yinyin Yuan; Rajendra Singh; Crispin Hiley; Maise Al Bakir; Alexander J Lazar; Stephen Naber; Stephan Wienert; Miluska Castillo; Giuseppe Curigliano; Maria-Vittoria Dieci; Fabrice André; Charles Swanton; Jorge Reis-Filho; Joseph Sparano; Eva Balslev; I-Chun Chen; Elisabeth Ida Specht Stovgaard; Katherine Pogue-Geile; Kim R M Blenman; Frédérique Penault-Llorca; Stuart Schnitt; Sunil R Lakhani; Anne Vincent-Salomon; Federico Rojo; Jeremy P Braybrooke; Matthew G Hanna; M Teresa Soler-Monsó; Daniel Bethmann; Carlos A Castaneda; Karen Willard-Gallo; Ashish Sharma; Huang-Chun Lien; Susan Fineberg; Jeppe Thagaard; Laura Comerma; Paula Gonzalez-Ericsson; Edi Brogi; Sherene Loi; Joel Saltz; Frederick Klaushen; Lee Cooper; Mohamed Amgad; David A Moore; Roberto Salgado
Journal:  NPJ Breast Cancer       Date:  2020-05-12

Review 5.  Report on computational assessment of Tumor Infiltrating Lymphocytes from the International Immuno-Oncology Biomarker Working Group.

Authors:  Mohamed Amgad; Elisabeth Specht Stovgaard; Eva Balslev; Jeppe Thagaard; Weijie Chen; Sarah Dudgeon; Ashish Sharma; Jennifer K Kerner; Carsten Denkert; Yinyin Yuan; Khalid AbdulJabbar; Stephan Wienert; Peter Savas; Leonie Voorwerk; Andrew H Beck; Anant Madabhushi; Johan Hartman; Manu M Sebastian; Hugo M Horlings; Jan Hudeček; Francesco Ciompi; David A Moore; Rajendra Singh; Elvire Roblin; Marcelo Luiz Balancin; Marie-Christine Mathieu; Jochen K Lennerz; Pawan Kirtani; I-Chun Chen; Jeremy P Braybrooke; Giancarlo Pruneri; Sandra Demaria; Sylvia Adams; Stuart J Schnitt; Sunil R Lakhani; Federico Rojo; Laura Comerma; Sunil S Badve; Mehrnoush Khojasteh; W Fraser Symmans; Christos Sotiriou; Paula Gonzalez-Ericsson; Katherine L Pogue-Geile; Rim S Kim; David L Rimm; Giuseppe Viale; Stephen M Hewitt; John M S Bartlett; Frédérique Penault-Llorca; Shom Goel; Huang-Chun Lien; Sibylle Loibl; Zuzana Kos; Sherene Loi; Matthew G Hanna; Stefan Michiels; Marleen Kok; Torsten O Nielsen; Alexander J Lazar; Zsuzsanna Bago-Horvath; Loes F S Kooreman; Jeroen A W M van der Laak; Joel Saltz; Brandon D Gallas; Uday Kurkure; Michael Barnes; Roberto Salgado; Lee A D Cooper
Journal:  NPJ Breast Cancer       Date:  2020-05-12

6.  Reliability of tumor-infiltrating lymphocyte and tertiary lymphoid structure assessment in human breast cancer.

Authors:  Laurence Buisseret; Christine Desmedt; Soizic Garaud; Marco Fornili; Xiaoxiao Wang; Gert Van den Eyden; Alexandre de Wind; Sebastien Duquenne; Anais Boisson; Celine Naveaux; Francoise Rothé; Sandrine Rorive; Christine Decaestecker; Denis Larsimont; Martine Piccart-Gebhart; Elia Biganzoli; Christos Sotiriou; Karen Willard-Gallo
Journal:  Mod Pathol       Date:  2017-06-16       Impact factor: 7.842

7.  Utilizing Automated Breast Cancer Detection to Identify Spatial Distributions of Tumor-Infiltrating Lymphocytes in Invasive Breast Cancer.

Authors:  Han Le; Rajarsi Gupta; Le Hou; Shahira Abousamra; Danielle Fassler; Luke Torre-Healy; Richard A Moffitt; Tahsin Kurc; Dimitris Samaras; Rebecca Batiste; Tianhao Zhao; Arvind Rao; Alison L Van Dyke; Ashish Sharma; Erich Bremer; Jonas S Almeida; Joel Saltz
Journal:  Am J Pathol       Date:  2020-04-08       Impact factor: 4.307

Review 8.  Advancing Immunotherapy in Metastatic Breast Cancer.

Authors:  Mariam Mansour; Zhi Ling Teo; Stephen J Luen; Sherene Loi
Journal:  Curr Treat Options Oncol       Date:  2017-06

9.  A Multigene Assay Determines Risk of Recurrence in Patients with Triple-Negative Breast Cancer.

Authors:  Rachel L Stewart; Katherine L Updike; Rachel E Factor; N Lynn Henry; Kenneth M Boucher; Philip S Bernard; Katherine E Varley
Journal:  Cancer Res       Date:  2019-05-02       Impact factor: 12.701

10.  Tumour-infiltrating lymphocytes in advanced HER2-positive breast cancer treated with pertuzumab or placebo in addition to trastuzumab and docetaxel: a retrospective analysis of the CLEOPATRA study.

Authors:  Stephen J Luen; Roberto Salgado; Stephen Fox; Peter Savas; Jennifer Eng-Wong; Emma Clark; Astrid Kiermaier; Sandra M Swain; Jose Baselga; Stefan Michiels; Sherene Loi
Journal:  Lancet Oncol       Date:  2016-12-07       Impact factor: 41.316

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.